Dr Kieron Wesson

Dr Kieron Wesson

Kezar Life Sciences

ABOUT

Kieron Wesson is currently a consultant with over 20 years of experience in the pharmaceutical industry focused in manufacturing development and regulatory CMC for drug substances (API) and finished drug products. He has contributed to drug programs spanning clinical to commercial stages, most recently as Senior Executive of CMC at Kezar Life Sciences.

Earlier in his career, Kieron worked on several boron-containing drugs, including Kerydin® (tavaborole) and Eucrisa® (crisaborole) — both among only a handful of commercially approved boron-based drugs and which were brought to market by Anacor Pharmaceuticals (now a subsidiary of Pfizer). He was then among the first employees at AN2 Therapeutics, where he led the pharmaceutical development of epetraborole, another boron-containing drug and novel antibiotic now in pivotal clinical trials.

Kieron completed his BA in Natural Sciences at the University of Cambridge under the supervision of Dr. Stuart Warren and continued there to obtain his PhD with Prof. Steven Ley. He is based in the San Francisco Bay Area.